ICU MEDICAL, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.5 USD | -2.92% |
|
-3.59% | +2.72% |
| May. 08 | ICU Medical's Q1 Adjusted Earnings, Revenue Decline | MT |
| May. 07 | Earnings Flash (ICUI) ICU MEDICAL Reports Q1 Revenue $566.7M, vs. Street Est of $554M | MT |
Financials (USD)
| Sales 2024 * | 2.28B | Sales 2025 * | 2.36B | Capitalization | 2.57B |
|---|---|---|---|---|---|
| Net income 2024 * | -70M | Net income 2025 * | 41M | EV / Sales 2024 * | 1.74 x |
| Net Debt 2024 * | 1.38B | Net Debt 2025 * | 1.23B | EV / Sales 2025 * | 1.61 x |
| P/E ratio 2024 * |
-33.6
x | P/E ratio 2025 * |
162
x | Employees | 14,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on ICU Medical, Inc.
More recommendations
More press releases
More news
| 1 day | -3.93% | ||
| 1 week | -3.86% | ||
| Current month | +4.34% | ||
| 1 month | +4.51% | ||
| 3 months | -1.37% | ||
| 6 months | +20.23% | ||
| Current year | +2.44% |
1 week
101.72
107.16
1 month
93.36111.98
Current year
86.80123.46
1 year
78.28196.57
3 years
78.28282.00
5 years
78.28282.00
10 years
56.62321.70
| Managers | Title | Age | Since |
|---|---|---|---|
Vivek Jain
CEO | Chief Executive Officer | 52 | 14-02-12 |
Brian Bonnell
DFI | Director of Finance/CFO | 50 | 18-04-30 |
| Chief Tech/Sci/R&D Officer | - | 15-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 18-01-04 | |
Kolleen Kennedy
BRD | Director/Board Member | 63 | 21-12-30 |
Vivek Jain
CEO | Chief Executive Officer | 52 | 14-02-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 14 M€ | -3.15% | ||
| 0.65% | 2 M€ | 0.00% | ||
| 0.38% | 8 M€ | 0.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 102.5 | -2.94% | 98 955 |
| 24-05-22 | 105.6 | +2.78% | 273,371 |
| 24-05-21 | 102.7 | -0.48% | 137,872 |
| 24-05-20 | 103.2 | -0.72% | 112,534 |
| 24-05-17 | 104 | -2.15% | 121,225 |
Delayed Quote Nasdaq, May 23, 2024 at 11:20 am EDT
More quotes
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
105.6
USD
Average target price
142.2
USD
Spread / Average Target
+34.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.44% | 2.57B | |
| -5.29% | 182B | |
| +1.04% | 114B | |
| -5.49% | 67.76B | |
| +4.06% | 51.91B | |
| +7.21% | 43.23B | |
| +6.07% | 41.07B | |
| +22.81% | 32.07B | |
| +15.86% | 25B | |
| -2.65% | 24.55B |
- Stock Market
- Equities
- ICUI Stock
